MLN0905( MLN0905 | MLN 0905 | MLN-0905 )

Catalog No. M17207 CAS No. 1228960-69-7

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

MLN0905
Note

Research use only, not for human use.
Brief Description

MLN0905 is an effective PLK1 inhibitor(IC50=2 nM).
Description

MLN0905 is a potent, selective small-molecule PLK1 inhibitor. MLN0905 inhibits cell proliferation in a broad range of human tumor cells including DLBCL cell lines. PLK1 inhibition leads to pharmacodynamic pHisH3 modulation and significant antitumor activity in multiple DLBCL models. These data strongly suggest evaluating PLK1 inhibitors as DLBCL anticancer agents in the clinic. (source: Mol Cancer Ther; 11(9); 2045-53.)
In Vitro

——
In Vivo

Animal Model:Tumor (HT29) xenograft modelDosage:0-50 mg/kg Administration:P.O; daily, QD×3/week Result:Observed antitumor activity, tumor stasis or regression and well-tolerated oral doses.
Synonyms

MLN0905 | MLN 0905 | MLN-0905
Pathway

Metabolic Enzyme/Protease
Target

Factor Xa
Recptor

PLK1
Research Area

Cancer
Indication

——

CAS Number

1228960-69-7
Formula Weight

486.56
Molecular Formula

C24H25F3N6S
Purity

>98% (HPLC)
Solubility

DMSO : ≥ 30 mg/mL. 61.66 mM
SMILES

CN(C)CCCc1cc(Nc2ncc3CC(=S)Nc4c(ccc(c4)C(F)(F)F)c3n2)c(C)nc1
Chemical Name

2-((5-(3-(dimethylamino)propyl)-2-methylpyridin-3-yl)amino)-9-(trifluoromethyl)-5H-benzo[b]pyrimido[4,5-d]azepine-6(7H)-thione

1. Duffey MO, et al. J Med Chem, 2012, 55(1), 197-208.

Calculator

molnova catalog